More recently, a population-based screening of breast cancer susceptibility genes in China further confirmed the prognostic value of PALB2 in breast cancer; patients with a PALB2 mutation presented shorter overall survival compared with noncarriers (adjusted hazard ratio, 8.38; 95% CI, 2.19–32.11; p = 0.002) (85). The gene discussed is PALB2; the disease is breast carcinoma.